BIIB Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 19% compared to Biogen, Inc.'s net margin of 31.72%. Biogen, Inc.'s return on equity of 9.36% beat Eli Lilly & Co.'s return on equity of 106.26%.

Biogen, Inc. has a consensus price target of $178.76, signalling downside risk potential of -1.1%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Eli Lilly & Co. has higher upside potential than Biogen, Inc., analysts believe Eli Lilly & Co. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.128, which suggesting that the stock is 87.226% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Biogen, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.5B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Biogen, Inc.'s net income of $466.5M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Biogen, Inc.'s price-to-earnings ratio is 16.48x while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.74x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of 33.68%. Biogen, Inc.'s return on equity of 9.36% beat Merck & Co., Inc.'s return on equity of 39.63%.

Biogen, Inc. has a consensus price target of $178.76, signalling downside risk potential of -1.1%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that Merck & Co., Inc. has higher upside potential than Biogen, Inc., analysts believe Merck & Co., Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.128, which suggesting that the stock is 87.226% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. Biogen, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.5B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Biogen, Inc.'s net income of $466.5M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Biogen, Inc.'s price-to-earnings ratio is 16.48x while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.74x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of 21.32%. Biogen, Inc.'s return on equity of 9.36% beat Pfizer Inc.'s return on equity of 10.84%.

Biogen, Inc. has a consensus price target of $178.76, signalling downside risk potential of -1.1%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than Biogen, Inc., analysts believe Pfizer Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.128, which suggesting that the stock is 87.226% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Biogen, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.5B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Biogen, Inc.'s net income of $466.5M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Biogen, Inc.'s price-to-earnings ratio is 16.48x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.74x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of -360.68%. Biogen, Inc.'s return on equity of 9.36% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Biogen, Inc. has a consensus price target of $178.76, signalling downside risk potential of -1.1%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 2.15%. Given that Stoke Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.128, which suggesting that the stock is 87.226% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.807%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.5B, which are larger than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Biogen, Inc.'s net income of $466.5M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Biogen, Inc.'s price-to-earnings ratio is 16.48x while Stoke Therapeutics, Inc.'s PE ratio is 46.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.74x versus 8.78x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.